Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.
18 February 2025 in Methodist DeBakey Cardiovascular Journal
Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in the United States. These conditions are caused by a combination of factors, including genetic, behavioral, environmental, and medical influences. Obesity is a major risk factor for cardiovascular and metabolic diseases. A comprehensive treatment plan for individuals with obesity must recognize the chronic nature of the condition and offer strategies for weight reduction and long-term cardiometabolic benefits. Over the past several decades, multiple therapeutic options have been implemented to address weight loss, appetite regulation, and caloric expenditure, with the goal of reducing the burden of obesity and improving cardiovascular outcomes. Pharmacological treatment of obesity has focused primarily on the central regulation of appetite and food intake behavior. The introduction of incretin agonists for obesity treatment has ushered in a new era of cardiometabolic health, with a multitargeted mechanism that achieves weight loss, glycemic control, decreased cardiovascular mortality, and other metabolic benefits. This review explores the current pharmacological options and the future of obesity treatment.
Background: Anemia is common in post-transplant patients. Blood product transfusion is associated with mortality and rejection in solid organ transplants. In lung transplant recipients, transfusion predisposes to primary graft dysfunction (PGD). The adverse effects and associated mortality of perioperative transfusions in lung transplant recipients have not been evaluated. This study examined the effects of perioperative blood transfusions in lung transplant recipients. Material/Methods: We conducted a retrospective study of the effects of blood product transfusions in patients who received single- or double-lung transplantation at Houston Methodist Hospital between August 2017 and September 2019. Univariable and multiple logistic regression modeling were used to determine the characteristics associated with single events as well as a composite outcome within 30 days (including mortality, acute myocardial infarction, acute stroke, lower respiratory tract infection, urinary tract infection, surgical site infections, or PGD). Results: A total of 232 patients received lung transplants between December 2015 and September 2019 at our center. Univariable analysis revealed an increased risk of PGD (P<0.001), more mechanical ventilation days (P<0.001), more ICU days post-transplant (P<0.001), and greater need for ECMO support (P=0.001) in patients who received blood product transfusions. In univariate analysis, the composite outcome was also more common (P=0.01) in patients who received any transfusion perioperatively. A total of 7 patients died within 30 days from transplant, and they were all in the transfused group. Conclusions: Among lung transplant recipients, PGD, ICU days, need for mechanical ventilation and ECMO support, and total composite events were significantly greater in patients who received blood transfusion perioperatively.
Context: Severe thyrotoxicosis and thyroid storm have a high morbidity and mortality risk and are commonly managed with antithyroid drugs. In some patients, a combination therapy with medications and thyroidectomy as definite treatment are required. Therapeutic Plasma Exchange (TPE) can be used as a temporizing measure to achieve thyroid hormone normalization and to prevent perioperative complications before surgery. Objective: We describe 6 cases of severe thyrotoxicosis and/or thyroid storm who underwent TPE as a bridge to thyroidectomy and present the clinical characteristics and outcomes. We aim to propose a preoperative thyroid hormone target. Methods: We collected data of 6 patients who were diagnosed with severe thyrotoxicosis or thyroid storm between April 2023 and April 2024 and that were treated with TPE due to high mortality risk or refractoriness to medical treatment. Data collected included the baseline clinical characteristics, laboratory data, clinical progress, and outcomes. Thyroid hormone levels at diagnosis, before initiation of TPE, and before thyroidectomy were compared using statistical analysis. Results: Four of 6 patients underwent thyroidectomy, and 2 patients died due to multiorgan dysfunction. The mean free T4 (fT4) level at diagnosis was 4.8 ng/dL (reference range, 0.8-1.8 ng/dL), 5.4 ng/dL pre-TPE, and 2.6 ng/dL prethyroidectomy, resulting in a mean difference of 2.8 ng/dL (51.7%) reduction (95% CI, 1.1-4.5; P = .01). The number of TPE treatments to reach a preoperative fT4 level of 2.5 ng/dL was 5.5 treatments (P = .03). Conclusion: These results reflect efficacy of TPE as a bridge to thyroidectomy and suggest that a preoperative fT4 goal of 2.5 to 3.3 can be considered in patients with severe thyrotoxicosis and thyroid storm that are refractory to medical treatment.